InvestmentJun 18, 2026, 04:56 PM
IceCure Medical Prices $5.5M Private Placement at Premium
AI Summary
IceCure Medical Ltd. announced a private placement offering to an institutional investor, expecting to raise approximately $5.5 million in gross proceeds. The offering includes pre-funded warrants and Series D and E warrants to purchase 1,833,334 ordinary shares each, priced at $2.9999 per pre-funded warrant and accompanying warrants. The company also agreed to amend existing Series B and C warrants, reducing their exercise price from $16.50 to $3.00 per share, subject to shareholder approval. Separately, the company reported a 70% growth in its U.S. active commercial install base for breast cancer cryoablation following FDA clearance.
Key Highlights
- Private placement to raise approximately $5.5 million in gross proceeds.
- Issued pre-funded warrants for 1,833,334 ordinary shares at $0.0001 exercise price.
- Issued Series D and E warrants for 1,833,334 ordinary shares each at $3.00 exercise price.
- Amended existing Series B and C warrants, reducing exercise price from $16.50 to $3.00 per share, subject to shareholder approval.
- Placement agent A.G.P./Alliance Global Partners to receive a 7.0% cash fee.
- U.S. active commercial install base for breast cancer cryoablation grew by 70%.
- Net proceeds from the offering will be used for working capital and general corporate purposes.
Price Impact
More from ICCM